drugset / Trial / NCT02473562
Varenicline Treatment for Excessive Daytime Sleepiness in Parkinson's Disease
Phase 4
Terminated
22 enrolled
Amsterdam UMC, location VUmc
Centre for Human Drug Research, Netherlands · collab
RandomizedCrossoverDouble-blindTreatment
Summary
The effect of varenicline, an alpha4beta2 nicotinic receptor partial agonist on excessive daytime sleepiness in Parkinson's disease will be studied in a randomized, double blind, placebo-controlled clinical trial with a within-subject crossover design.
Timeline
- Start
- 2013-05
- Primary completion
- 2018-01
- Completion
- 2018-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Varenicline | Small molecule | 1 mg | — |